Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Issued (2020 - 2024)

4D Molecular Therapeutics (FDMT) has disclosed Shares Issued for 5 consecutive years, with $37000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Shares Issued rose 100.03% to $37000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $15.3 million, a 20.05% decrease, with the full-year FY2024 number at $15.3 million, down 20.05% from a year prior.
  • Shares Issued was $37000.0 for Q4 2024 at 4D Molecular Therapeutics, up from -$19.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $204.7 million in Q4 2020 to a low of -$110.1 million in Q4 2023.
  • A 5-year average of $27.2 million and a median of $99000.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 14763.31% in 2023, then tumbled 115.31% in 2024.
  • 4D Molecular Therapeutics' Shares Issued stood at $204.7 million in 2020, then plummeted by 44.16% to $114.3 million in 2021, then crashed by 100.77% to -$875000.0 in 2022, then plummeted by 12479.66% to -$110.1 million in 2023, then surged by 100.03% to $37000.0 in 2024.
  • Per Business Quant, the three most recent readings for FDMT's Shares Issued are $37000.0 (Q4 2024), -$19.6 million (Q2 2024), and $34.9 million (Q1 2024).